Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. (SHPH), a Delaware corporation and emerging growth company, filed this Form 8-K on September 2, 2022. The report details the closing of its firm commitment initial public offering (IPO) on the same date.
Key Financial Metrics
- Gross Proceeds: $9,960,340 (before underwriting discounts, commissions, and estimated offering expenses).
- Units Sold: 1,225,888 units.
- Offering Price: $8.125 per unit.
- Unit Composition: One share of Common Stock ($0.00001 par value) and one Warrant to purchase one share of Common Stock.
- Warrant Exercise: All warrants were exercised simultaneously with the closing of the IPO.
- Over-Allotment Option: Underwriters were granted a 45-day option to purchase up to an additional 183,883 units.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity, as this is a transaction report rather than a periodic financial statement.
Material Changes
The primary material change is the transition to a publicly traded company on The Nasdaq Stock Market LLC under the symbol "SHPH." The company raised approximately $9.96 million in gross proceeds through the sale of units, significantly altering its capital structure compared to the pre-IPO period.
Guidance, Outlook, and Risks
This filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosures associated with an IPO. The transaction was conducted pursuant to a registration statement on Form S-1 declared effective by the SEC on August 29, 2022. Boustead Securities, LLC acted as the lead underwriter, with Valuable Capital, Ltd. as the co-underwriter.
Investor Verification Checklist
- Verify the net proceeds after deducting underwriting discounts, commissions, and offering expenses, as only gross proceeds are listed here.
- Confirm the total number of shares outstanding post-IPO, accounting for the simultaneous exercise of all warrants.
- Review the full Form S-1 (File No. 333-265429) for detailed risk factors and use of proceeds.
- Monitor the status of the 45-day over-allotment option to determine if additional capital will be raised.